EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Amyloid-beta antibody treatment in Alzheimer’s disease

Elisabeth Stögmann, Reinhold Schmidt

Wiener klinische Wochenschrift · 2025

DOI: 10.1007/s00508-024-02466-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Elisabeth Stögmann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria. elisabeth.stoegmann@meduniwien.ac.at. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyloid-beta (Aβ) antibody treatment has emerged as a promising approach for the treatment of Alzheimer’s disease (AD), targeting the accumulation of Aβ plaques, which are a hallmark of the disease. This review provides an update on recent clinical trial data, highlighting the efficacy and safety of various antibodies targeting Aβ. Recent trials have demonstrated that certain Aβ antibodies can reduce amyloid plaques and slow cognitive decline in patients with early AD. Key findings from trials of drugs are discussed, including their mechanisms of action, dosing regimens, and observed side effects. The potential for Aβ antibody therapy to be integrated into routine clinical practice is also explored. While Aβ antibody therapy represents a significant advancement in AD treatment, ongoing research is needed to optimize their use and understand their long-term impact. This review underscores the importance of personalized medicine in AD and the need for continued innovation in therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalHumansTreatment OutcomeEvidence-Based MedicinePlaque, AmyloidAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AlzheimerDementiaMonoclonal antibodyNew therapeutic strategyUse recommendation

Substanzen

Amyloid beta-PeptidesAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria. elisabeth.stoegmann@meduniwien.ac.at.
  • Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036, Graz, Austria.

Förderung

  • Medical University of Vienna

Zitieren

APA

Stögmann, E., & Schmidt, R. (2025). Amyloid-beta antibody treatment in Alzheimer’s disease. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02466-7

Vancouver

Stögmann E, Schmidt R. Amyloid-beta antibody treatment in Alzheimer’s disease. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-024-02466-7

BibTeX
@article{Stgmann2025,
  author = {Stögmann, Elisabeth and Schmidt, Reinhold},
  title = {Amyloid-beta antibody treatment in Alzheimer’s disease},
  journal = {Wiener klinische Wochenschrift},
  year = {2025},
  doi = {10.1007/s00508-024-02466-7}
}
Kostenlos starten →